Avilar Therapeutics, Inc.
USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids).
The verdict
According to USPTO PatentsView, Avilar ranks #34,373 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.
- #34,373
- of 49,997 US assignees by volume
- Top 16%
- by Innovation Score (48.9/100)
- 23.0
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R34373 · US Corporation #34,373 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 7 grants
- MID-PACK #34,373/49,997
- PHOTO-FINISH Automotive Test…
- CPC-NARROW C07H · 5 areas
- INNOV-PAR 48.9/100
- CLAIMS-DENSE 23.0 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2023–2025 · 3y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Automotive Test Solutions, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Avilar’s 48.9 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Avilar
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Avilar Therapeutics · this assignee
Avilar Therapeutics · this assignee
49 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Avilar's Innovation Score is 48.9/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Avilar?
Each dot is one of Avilar’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Avilar’s own 23.0 claims/patent is ABOVE the 11.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Avilar's grants concentrate
Avilar Therapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2023. By volume, Avilar sits between Automotive Test Solutions, Inc. and Axetris AG.
Avilar's three-year grant acceleration
Avilar Therapeutics, Inc. shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Avilar's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Automotive Test S…
Automotive Test Solutions, Inc.
7 patents
- Avanpore
Avanpore LLC
7 patents
- Avero AB
Avero AB
7 patents
- Avid
Avid, Inc.
7 patents
- Avon Polymer Prod…
Avon Polymer Products Limited
7 patents
- Avoscience
Avoscience, LLC
7 patents
- Axalume
Axalume, Inc.
7 patents
- Axetris
Axetris AG
7 patents
- Avilar Therapeuti… ◀
Avilar Therapeutics, Inc.
7 patents
What this shows Avilar holds 7 patents at rank #34,382, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Avilar
By rank, the assignees closest to #34,382 in granted patent volume.
Leaders in C07H (Sugars)
Other assignees with the most granted patents in Avilar's primary technology class.
- Ionis Pharmaceuticals, Inc. 84 in class
- President and Fellows of Harvard College 65 in class
- Life Technologies Corporation 57 in class
- Alnylam Pharmaceuticals, Inc. 56 in class
- Gilead Sciences, Inc. 53 in class
- The Trustees of Columbia University in the City of New York 50 in class
- Illumina Cambridge Limited 50 in class
- Merck Sharp & Dohme LLC 49 in class
Avilar's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
49 Top 16% higher than 84% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 1 | 14.3% |
| 2024 | 3 | 42.9% |
| 2025partial year | 3 | 42.9% |
Which technologies does Avilar Therapeutics, Inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Avilar Therapeutics, Inc.'s patent record in context - here's where to go next.
- Avilar Therapeutics, Inc.'s lead technology class is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids), 100% of its portfolio - see every assignee active in that class. Explore C07H
- Ranked #34,373 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Avilar Therapeutics, Inc. against Automotive Test Solutions, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 48.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.